Lantern Pharma
LTRN
27 hedge funds and large institutions have $3.93M invested in Lantern Pharma in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
8% more funds holding
Funds holding: 25 → 27 (+2)
0.01% more ownership
Funds ownership: 10.61% → 10.62% (+0.01%)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
39% less capital invested
Capital invested by funds: $6.5M → $3.93M (-$2.56M)
65% less call options, than puts
Call options by funds: $8K | Put options by funds: $23K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFA
Pathway Financial Advisors
South Burlington,
Vermont
|
+$85.2K |
| 2 |
MWM
Meridian Wealth Management
Lexington,
Kentucky
|
+$75.7K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$26.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$22.8K |
| 5 |
JP Morgan Chase
New York
|
+$41 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WWM
Wolff Wiese Magana
Carslbad,
California
|
-$104K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$59.7K |
| 3 |
Renaissance Technologies
New York
|
-$30.9K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$6.56K |
| 5 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$6.51K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Qube Research & Technologies (QRT)
London,
United Kingdom
| $7 | +$9 | +2 | New |
|
|
27
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$59.7K | -10,581 | Closed |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$454 | -100 | -49% |
|
LTRN Hedge Fund Activity: Q3 2023 in Review
27 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q3 2023, worth a combined $3.93M — down 39% from $6.5M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LTRN positions and 1 closed out — a net gain of 2 holders — while 5 added to existing stakes and 8 trimmed.
The largest buyer was Pathway Financial Advisors, adding an estimated $85.2K. The largest seller was Wolff Wiese Magana, cutting an estimated $104K.
- 27 institutional investors held Lantern Pharma (LTRN) as of Q3 2023, up from 25 in Q2 2023.
- Funds reported $3.93M of Lantern Pharma stock for Q3 2023, down 39% quarter-over-quarter.
- 3 funds opened new Lantern Pharma positions in Q3 2023 and 1 closed out, a net change of +2 holders.
- The largest Lantern Pharma buyer in Q3 2023 was Pathway Financial Advisors, an estimated $85.2K added.
- The largest Lantern Pharma seller in Q3 2023 was Wolff Wiese Magana, an estimated $104K sold.
Based on aggregated 13F filings for Q3 2023.